---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-101825"
form_type: "8-K"
ticker: "ORMP"
cik: "0001176309"
company_name: "ORAMED PHARMACEUTICALS INC."
filed_at: "2025-10-24T23:59:59+00:00"
generated_at: "2026-05-17T02:18:48.433886+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Oramed terminates HTIT joint venture, repurchases 1.15M shares, reports ~$210M in assets, launches new insulin trial

## Summary
- Repurchased 1,155,367 shares from HTIT Biotech at $2.23/share for $2.58M total; shares cancelled.
- Terminated joint venture with HTIT after it failed to satisfy closing conditions; oral insulin program to continue independently.
- Preliminary unaudited cash and assets ~$210M as of Sep 30, 2025, up from $155.7M in Jan 2023.
- Initiating 60-patient US oral insulin trial targeting high-responder subgroups (lower BMI, older) for >1% HbA1c reduction.
- Investment portfolio: $27.1M unrealized gain on Alpha Tau ($64.8M position); Scilex loan returned $95.5M of $99.5M.

## SEC filing metadata
- accession: 0001213900-25-101825
- form_type: 8-K
- ticker: ORMP
- cik: 0001176309
- company_name: ORAMED PHARMACEUTICALS INC.
- filed_at: 2025-10-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 1.02, 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1176309/000121390025101825/0001213900-25-101825-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1176309/000121390025101825/ea0262319-8k_oramed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-101825
- JSON: https://secwatch.observer/filing/0001213900-25-101825.json
- Plain text: https://secwatch.observer/filing/0001213900-25-101825.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.